Dr. Peter Takacs
Global Head of Market Access Miletenyi Biomedicine
Dr. Peter Takacs is a global market access leader at Miltenyi Biomedicine, specialising in pricing, reimbursement, and evidence generation strategies for innovative therapies. With extensive experience across both large pharmaceutical organisations and biotech, he focuses on developing and executing access strategies for complex treatments, including cell and gene therapies. Peter brings deep expertise in real-world evidence, innovative access schemes, and navigating diverse global reimbursement systems.
Seminars
Tuesday 20th October 2026
Early Access in Europe: A Working Theory for Greater Alignment Across Systems
9:00 am
- Examining fragmentation across European early access pathways and the resulting challenges for industry payers and HTA decision making
- Exploring a working theory for greater alignment of early access policies across Europe drawing parallels with emerging EU frameworks such as joint clinical assessment
- Evaluating potential impacts of greater alignment including operational feasibility legal considerations and competitive dynamics across similar therapies
